20Med Therapeutics is a Dutch biotechnology company developing innovative solutions for efficient intracellular delivery of (oligo)nucleotide therapeutics (siRNA, miRNA, mRNA, DNA) for treatment of genetic diseases. 20Med’s proprietary nanogels are highly innovative nanoparticles, designed with several smart bioresponsive functions making them efficient in transport, cellular uptake, and release of active gene and drug molecules into the cytoplasm of target cells. 20Med Nanogels are flexible in functionalization and their unique properties make them applicable to a broad range of medical therapeutics. 20Med Therapeutics was founded as a spin-off company of the University of Twente, based on the discovery of a novel generation of polymeric nanoparticles with a unique combination of chemical and biological properties essential for successful intracellular delivery of (oligo)nucleotides. Supported by Twente Technology Fund, 20Med has further developed these nanoparticles towards a proprietary platform of bioresponsive multifunctional polymeric nanogels. 20Med Nanogels are non-toxic and can be easily loaded with genetic materials, giving unprecedented efficacy in intracellular delivery and functional activity of gene therapeutics into targeted cells. The company`s strategy is to further exploit the high potential of 20Med`s delivery technology for application in a diversity of gene related diseases, and to demonstrate their great potential for safe and efficient gene therapy in a clinical setting. 20Med Therapeutics is headquartered in Enschede, NL.

Johan is the founder of 20Med Therapeutics BV and em. professor of Biomedical Chemistry at the Technical Medical Centre of the University of Twente. His research during the last 15 years has focused on the development of multifunctional nanosystems for controlled drug and gene delivery. Based on an innovative class of highly effective gene delivery carriers developed in his research he founded 20Med Therapeutics in 2011 as a spin-off company of the University of Twente.

Jaap Rip is VP R&D at 20Med Therapeutics. Prior to joining 20Med, Jaap held leadership positions at Nanomi BV, Eyesiu Medicines BV and BBB Therapeutics. He is trained as a Biologist at Wageningen University and obtained a PhD at the Amsterdam Medical Center (AMC). Jaap has a specific focus on the preclinical development, scale-up and manufacturing of complex injectable formulations with a strong background in polymer and lipid based (nano)particles for sustained release and targeted drug delivery.